Molecular and Genetic Analysis of Lung Cancer
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 15,000
- 试验地点
- 1
- 主要终点
- Survival among patients at different stages of lung cancer and treatment will be measured using questionnaires along with medical chart data to monitor treatment and disease progression
研究概览
简要总结
Investigators use a genome-wide approach within a case-control design to identify SNPs that show evidence of association with lung cancer risk and survival.
详细描述
Investigators also investigate how genetic variants may affect cancer treatment, at various stages of disease development, in order to determine prognostic and predictive factors for survival.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •healthy controls: participants without evidence of any cancer
- •cases: pathology proven primary lung cancer
排除标准
- •younger than 18 years old
结局指标
主要结局
Survival among patients at different stages of lung cancer and treatment will be measured using questionnaires along with medical chart data to monitor treatment and disease progression
时间窗: 20 years
Study lung cancer development in a case control study. We will look at three separate outcome measures specified below
次要结局
- Overall survival(20 years)
- Progression-free survival(20 years)
- Treatment toxicities(20 years)
研究者
David Christopher Christiani
Elkan Blout Professor at Harvard TH Chan School of Public Health, Professor of Medicine Harvard Medical School
Massachusetts General Hospital